Table: Taisho Pharmaceutical HD - 9-MTH group results
Feb 13 (Reuters)-
Taisho Pharmaceutical Holdings Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Dec 31, 2023 Dec 31, 2022 Mar 31, 2024
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 246.67 227.67
(+8.3 pct) (+13.8 pct)
Operating 19.02 23.12
(-17.8 pct) (+224.2 pct)
Recurring 23.72 29.17
(-18.7 pct) (+153.8 pct)
Net 10.32 20.90
(-50.6 pct) (+132.9 pct)
EPS 125.93 yen 254.93 yen
EPS Diluted 125.75 yen 254.60 yen
Ann Div 100.00 yen 50.00 yen
-Q2 div 50.00 yen 50.00 yen
-Q4 div 50.00 yen NIL
NOTE - Taisho Pharmaceutical Holdings Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4581.T
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10